HMG-CoA reductase inhibitors which are highly dependent on CYP3A4 metabolism, such as lovastatin and simvastatin, are expected to have markedly increased plasma concentrations when co-administered with VIRACEPT.
HMG- CoA reduktaasi inhibiitorite simvastatiini ja lovastatiini ainevahetus sõltub oluliselt CYP3A4 isoensüümist, mistõttu suureneb nende kontsentratsioon VIRACEPT’ iga koos võtmisel oluliselt.